Follow The Filings

PHAT Phathom Pharmaceuticals Inc.

Health Care, filed as PHATHOM PHARMACEUTICALS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2, sold by 1

  • 2 Owners
  • Max 0.4%
  • $4.2M
  • 1 new 1 reduce

In 2026 Q2 James Silverman opened a position in Phathom Pharmaceuticals, while David Witzke trimmed.

Who owns this now

Largest portfolio weights among holders, up to 0.4% (David Witzke, Avidity Partners Management). Not free-float ownership.

  1. David Witzke Reduce 0.35%
  2. James Silverman New 0.18%

Who owns PHAT

Sorted by value, long equity only, as of 2026 Q2.

History
David Witzke, Avidity Partners Management 0.35%, was 0.63% Reduce −19.8% 200,000 $2.2M History
James Silverman, Opaleye Management 0.18% New 0.18% 185,589 $2M History

2 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by PHAT's executives, directors and 10% owners in the last 12 months, from their Form 4s

All PHAT insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales

No open-market buys or sales on file.

Also filed in the last 12 months, not counted as buying or selling: 16 stock grants, 12 share withholdings for taxes, 6 gifts, 4 option exercises, and 1 sale to cover taxes.

SEC filings

Recent issuer filings from EDGAR, 21 shown.

Filed Form Detail Links
8-K 8.01 Filing Doc
8-K 8.01 Filing Doc
8-K 8.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 8.01 Filing Doc
8-K 5.07 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G — Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
SCHEDULE 13G/A — Filing Doc
424B5 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
424B5 Filing Doc

Source: SEC EDGAR submissions, updated 2 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $0.682M $55.25M $175.11M
Gross profit $0.515M $47.28M $152.51M
Gross margin * 75.5% 85.6% 87.1%
Net income -$201.59M -$334.33M -$221.25M
Net margin * -29558.9% -605.1% -126.3%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $397.43M $360.13M $228.97M
Total non-current assets * $16.41M $18.18M $30.18M
Total assets $413.84M $378.32M $259.15M
Total current liabilities $38.78M $85.73M $132.04M
Total non-current liabilities * $447.82M $546.17M $565.27M
Total equity -$72.76M -$253.58M -$438.17M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$137.58M -$266.77M -$166.78M
Cash from investing -$1.63M -$0.135M -$0.229M
Cash from financing $367.58M $182.77M -$0.288M
Net change in cash $228.37M -$84.13M -$167.29M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.